At Aurigene Pharmaceutical Services, we offer a wide range of integrated discovery biology services to meet your drug discovery needs. We offer end-to-end services including in vitro biology, ADME & DMPK studies, Toxicology, in vivo pharmacology and microbiology testing.
We provide integrated and standalone drug discovery services ranging from target identification to candidate nomination and further extension up to development services. Our best-in-class discovery biology services are supported by AAALAC accredited vivarium, BSL-2 compliant labs, in vivo facilities, GLP and other regulatory bodies accredited toxicology labs. Our discovery biology team offers a blend of scientific skills and pharmaceutical industry expertise with a proven track record of complex problem-solving capabilities. Biologists holding Masters, PhDs, and Postdocs are trained to undertake the most demanding drug discovery biology projects.
During the past two decades, the team in collaboration with our clients has been able to apply differentiated solutions to each aspect of drug discovery research, which has resulted in the discovery of many clinical candidates. Numerous research publications and feedback from clients are a testimony of our success.
Our team provides a wide range of services in biochemical assays, mechanistic assays, functional assays, immunological assays and various customized assays.
We provide precise data and insightful analysis of a drug's absorption, distribution, metabolism and excretion (ADME) properties. These insights help the clients to shortlist compounds with a high likelihood of success in later stages of drug development. DMPK tests include:
Our in vivo pharmacology team has expertise across multiple therapeutic areas. The team is supported by an AAALAC accredited, GLP-certified vivarium and experienced scientists who can set up diverse efficacy models as per program or client needs. We offer target engagement and efficacy models for:
These are validated with reference compounds and supported by histopathology and biomarker analysis.
Our pharmaceutical microbiology testing department has a BSL-2 compliant lab and a dedicated in vivo facility for bacterial and fungal infection murine disease models. Our team has vast experience in anti-infective drug discovery biology projects. The team has worked on several collaboration projects with innovator pharma companies to discover antibacterial and antifungal agents. We have also established in-vitro time-kill kinetics bioequivalence assays of generic products for regulatory submission.
We offer a full range of exploratory and GLP toxicology studies supported by clinical and anatomic pathology services, formulation analysis, toxicokinetic analysis and interpretation and reporting. General toxicology studies range from single-dose and repeat dose toxicology studies, genetic toxicology and IND and NDA enabling safety toxicology packages. We have a track record of successfully filing INDs using the in-house data with US FDA, MHRA, EMA, DCGI and ANDAs.
Expert team of scientists
65+ IDD projects delivered
US FDA inspected labs with zero 483 observations
AAALAC accredited animal house
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.